KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Assets: 2009-2025

Historic Assets for Novavax (NVAX) over the last 16 years, with Sep 2025 value amounting to $1.2 billion.

  • Novavax's Assets fell 31.10% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 31.10%. This contributed to the annual value of $1.6 billion for FY2024, which is 13.19% down from last year.
  • Per Novavax's latest filing, its Assets stood at $1.2 billion for Q3 2025, which was down 11.72% from $1.3 billion recorded in Q2 2025.
  • Novavax's Assets' 5-year high stood at $2.8 billion during Q1 2022, with a 5-year trough of $1.2 billion in Q3 2025.
  • In the last 3 years, Novavax's Assets had a median value of $1.6 billion in 2024 and averaged $1.5 billion.
  • Per our database at Business Quant, Novavax's Assets skyrocketed by 695.07% in 2021 and then crashed by 45.58% in 2023.
  • Over the past 5 years, Novavax's Assets (Quarterly) stood at $2.6 billion in 2021, then dropped by 12.34% to $2.3 billion in 2022, then dropped by 20.42% to $1.8 billion in 2023, then decreased by 13.19% to $1.6 billion in 2024, then tumbled by 31.10% to $1.2 billion in 2025.
  • Its Assets stands at $1.2 billion for Q3 2025, versus $1.3 billion for Q2 2025 and $1.3 billion for Q1 2025.